Ketty Peris, MD, Università Cattolica del Sacro Cuore & Universitario A. Gemelli IRCCS, Rome, Italy describes the current treatment options for basal cell carcinoma (BCC), which vary depending on the type of BCC and patient characteristics. Difficult to treat BCC lesions should be managed by a multidisciplinary team and available treatment options include hedgehog pathway inhibitors (HHIs) such as vismodegib and sonidegib and PD-1 inhibitors such as cemiplimab. Novel HHIs are currently being investigated in clinical trials for BCC alone and in combination with anti-PD-1 immunotherapies. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.

свернуть